“Profitability is on the horizon,” said Bordeaux-based UV disinfection solution company Germitec, following the company’s close of its $30m series B funding round on 12 February. The financing positions Germitec for sustained growth over the next two years, the company said.
The funding will support Germitec’s expansion into the US, said Vincent Gardès, CEO of Germitec, and for research and development to “maintain our commitment to developing cutting-edge disinfection solutions that...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?